A clinical risk score of myocardial fibrosis predicts adverse outcomes in aortic stenosis

Calvin W.L. Chin1,2*, David Messika-Zeitoun3, Anoop S.V. Shah1, Guillaume Lefevre4, Sophie Bailleul4, Emily N.W. Yeung1, Maria Koo1, Saeed Mirdadraee1, Tiffany Mathieu3, Scott I. Semple1, Nicholas L. Mills1, Alec Vahanian3, David E. Newby1, and Marc R. Dweck1

1British Heart Foundation/University Centre for Cardiovascular Science, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK; 2National Heart Center Singapore, Singapore, Singapore; 3Cardiology Department, AP-HP, Bichat Hospital, Paris, France; and 4Biochemistry Department, AP-HP, Tenon Hospital, Paris, France

Received 29 June 2015; revised 24 August 2015; accepted 17 September 2015

Aims
Midwall myocardial fibrosis on cardiovascular magnetic resonance (CMR) is a marker of early ventricular decompensation and adverse outcomes in aortic stenosis (AS). We aimed to develop and validate a novel clinical score using variables associated with midwall fibrosis.

Methods and results
One hundred forty-seven patients (peak aortic velocity ($V_{\text{max}}$) 3.9 [3.2,4.4] m/s) underwent CMR to determine midwall fibrosis (CMR cohort). Routine clinical variables that demonstrated significant association with midwall fibrosis were included in a multivariate logistic score. We validated the prognostic value of the score in two separate outcome cohorts of asymptomatic patients (internal: $n=127$, follow-up 10.3 [5.7,11.2] years; external: $n=289$, follow-up 2.6 [1.6,4.5] years). Primary outcome was a composite of AS-related events (cardiovascular death, heart failure, and new angina, dyspnoea, or syncope). The final score consisted of age, sex, $V_{\text{max}}$, high-sensitivity troponin I concentration, and electrocardiographic strain pattern [c-statistic 0.85 (95% confidence interval 0.78–0.91), $P<0.001$; Hosmer–Lemeshow $\chi^2=7.33$, $P=0.50$]. Patients in the outcome cohorts were classified according to the sensitivity and specificity of this score (both at 98%): low risk (probability score <7%), intermediate risk (7–57%), and high risk (>57%). In the internal outcome cohort, AS-related event rates were >10-fold higher in high-risk patients compared with those at low risk (23.9 vs. 2.1 events/100 patient-years, respectively; log rank $P<0.001$). Similar findings were observed in the external outcome cohort (31.6 vs. 4.6 events/100 patient-years, respectively; log rank $P<0.001$).

Conclusion
We propose a clinical score that predicts adverse outcomes in asymptomatic AS patients and potentially identifies high-risk patients who may benefit from early valve replacement.

Keywords
Aortic stenosis • Midwall myocardial fibrosis • Cardiovascular magnetic resonance imaging • High-sensitivity troponin I concentrations • Electrocardiogram strain

Introduction
In response to aortic stenosis (AS), left ventricular (LV) hypertrophy initially occurs as a compensatory response to maintain wall stress and cardiac output. Ultimately, the LV decompensates and heart failure ensues. The transition from adaptive LV hypertrophy to heart failure is characterized by myocyte death and myocardial fibrosis1–3 and is an important determinant of symptoms and adverse clinical outcomes. Myocardial fibrosis can be detected non-invasively using cardiovascular magnetic resonance (CMR), and increasing evidence has demonstrated the presence of midwall fibrosis as an early marker of ventricular decompensation and predictor of adverse cardiovascular outcomes in patients with AS.1–9

Despite its potential prognostic value, the widespread clinical utility of CMR is sometimes limited by cost, availability, and patient suitability. We have recently demonstrated two alternative and
more widely available markers of LV decompensation that are closely associated with the presence of midwall fibrosis.\textsuperscript{10,11} In separate studies, high-sensitivity plasma cardiac troponin I (cTnI) concentrations and the presence of LV hypertrophy with strain pattern on the electrocardiogram (ECG strain) were both independently associated with midwall fibrosis on CMR and adverse cardiovascular events, over and above conventional prognostic markers in AS.\textsuperscript{10,11} While high-sensitivity cTnI was a sensitive marker (100%) of midwall myocardial fibrosis, the ECG strain pattern was very specific (99%). The integration of these objective markers of LV decompensation into a clinical predictive score therefore represents a potentially attractive strategy of risk stratifying asymptomatic patients with AS and guiding the optimal timing of aortic valve replacement (AVR).

Using a novel approach, we aimed to develop a predictive score comprising variables associated with midwall myocardial fibrosis on CMR: a pathophysiologically relevant marker of early decompensation and adverse outcomes in AS. We then validated the prognostic impact of this clinical score in two large independent cohorts of asymptomatic patients with AS.

**Methods**

**Patient populations**

Three cohorts of patients were used in the study. A cohort of patients undergoing CMR was used to develop the clinical score to determine the probability of midwall myocardial fibrosis (CMR derivation cohort). This score was based on simple and widely available cardiac investigations. The prognostic value of this clinical score was then validated in two independent outcome cohorts of asymptomatic patients with an ejection fraction of $\geq 50\%$; an internal outcome cohort from the south-east of Scotland and an external outcome cohort from the Bichat Hospital, Paris. The study was conducted in accordance with the Declaration of Helsinki and was approved by the local research ethics committee. Written informed consent was obtained in all patients.

**Cardiovascular magnetic resonance derivation cohort**

The CMR derivation cohort consisted of stable patients with mild-to-severe AS. Patients were recruited from the outpatient clinics at the Edinburgh Heart Centre from March 2012 (clinicalTrials.gov identifier NCT01755936). Patients who had other significant valvular heart disease ($\geq$ moderate), contraindications to CMR or cardiomyopathies (acquired or inherited) were excluded. As this study aimed to identify variables of midwall myocardial fibrosis due to AS, we excluded patients with previous myocardial infarction based on clinical history and confirmed on CMR. Blood samples were taken at the time of CMR and clinical assessment.

**Internal outcome cohort**

This internal outcome cohort consisted of patients with AS initially recruited into the Scottish Aortic Stenosis and Lipid Lowering Trial, Impact of RRegression study. In brief, 155 asymptomatic patients were recruited between March 2001 and April 2002 to investigate the effects of intensive lipid-lowering therapy on AS progression.\textsuperscript{12}

**External outcome cohort**

The external outcome cohort comprised of asymptomatic patients with at least mild AS from the COFRASA and GENERAC studies (clinicalTrials.gov numbers NCT00338676 and NCT00647088, respectively). These patients were prospectively recruited since November 2006. Exclusion criteria were AS due to rheumatic valvular disease or radiotherapy, previous infective endocarditis, other significant valvular diseases ($\geq$ moderate), and severe respiratory or renal insufficiency.

**Electrocardiography**

A standard 12-lead ECG was performed in all patients. Electrocardiography strain was diagnosed with the Romhilt-Estes point system ($\geq$ 5 points)\textsuperscript{13} and the presence of $\geq 1$ mm concave downsloping ST depression with asymmetrical T-wave inversion in the lateral leads.\textsuperscript{14}

**Echocardiography**

All patients underwent comprehensive echocardiography to determine AS severity. Peak aortic jet velocity ($V_{\text{max}}$) and the mean pressure gradient were determined by velocity integral spectral Doppler, and the aortic valve area estimated using the continuity equation. The severity was assessed and classified according to the European Association of Echocardiography/American Society of Echocardiography guidelines.\textsuperscript{15}

**High-sensitivity cardiac troponin I and natriuretic peptide assays**

Plasma cTnI concentrations were determined across the three cohorts using a high-sensitivity assay (ARCHITECT\textsuperscript{\textregistered} STAT, Abbott Laboratories, IL, USA). The lower limit of detection for this assay was 1.2 ng/L and the concentration at 10% inter-assay imprecision was 4.7 ng/L. Concentrations lower than the detection levels were assigned a value of 1.2 ng/L. In the CMR derivation cohort, plasma brain natriuretic peptide (BNP) concentrations were determined using the Triage BNP assay (BioSite Inc., San Diego, CA, USA).\textsuperscript{16} In the internal and external outcome cohorts, plasma N-terminal pro-BNP concentrations were measured using the Elecsys 2010 analyzer (Roche Diagnostics Ltd, Lewes, UK).\textsuperscript{17} For both BNP assays, concentrations lower than the manufacturer-reported lower limit of detection were assigned the lowest value (5 pg/mL).

**Cardiovascular magnetic resonance in the cardiovascular magnetic resonance derivation cohort**

Cardiovascular magnetic resonance was performed using a 3T scanner (MAGNETOM Verio, Siemens AG, Healthcare Sector, Germany). Short-axis cines from the mitral valve annulus to the apex were used to assess LV volume, function, and mass (balanced steady-state free precision sequence; 8 mm parallel slices with 2 mm gap). All measurements were indexed to body surface area (Argus Ventricular Function, Siemens AG Healthcare Sector, Erlangen, Germany). Cardiovascular magnetic resonance LV longitudinal function was assessed using a method previously described.\textsuperscript{11}

The assessment of focal midwall myocardial fibrosis was performed using late gadolinium enhancement (LGE), 15 min following 0.1 mmol/kg of gadobutrol (Gadovist/Gadavist, Bayer Pharma AG, Germany). Two approaches were used: an inversion recovery fast gradient-echo sequence and a phase-sensitive inversion recovery sequence, performed in two phase-encoding directions to differentiate true late enhancement from artefact. The inversion time was optimized to achieve satisfactory nulling of the myocardium for the inversion-recovery images. Midwall LGE was determined qualitatively by two independent and experienced operators (C.W.L.C. and M.R.D.).

**Clinical outcomes**

The primary outcome of the study was AS-related events: a composite of cardiovascular mortality, congestive heart failure, and new symptoms of angina, syncope, or dyspnoea. The secondary outcomes were all-cause...
mortality and cardiovascular mortality. All events in the internal outcome cohort were adjudicated from the General Register of Scotland and verified by two independent investigators. Any discrepancy was resolved by consensus. In the external outcome cohort, events were adjudicated by experienced cardiologists blinded to any biological or ECG information. Patients in the internal and external outcome cohorts were followed until September 2012 and December 2014, respectively and events were censored at the time of last patient contact or at the time of AVR.

Statistical analysis
Baseline characteristics were reported as percentages for categorical variables, mean ± standard deviation or median (inter-quartile range) for continuous variables as appropriate. The distribution of all continuous variables was tested for normality using the Shapiro–Wilk test. Statistical analyses were performed using SPSS version 20 (IBM Corp., Armonk, NY, USA) and GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA). Statistical significance was taken as a two-sided P < 0.05.

Establishing determinants of midwall myocardial fibrosis
In the CMR derivation cohort, clinically relevant variables that demonstrated univariate association with midwall myocardial fibrosis (P < 0.20) were selected in the multivariate logistic model. Subsequently, backward elimination method was used to establish a best-fitting parsimonious model, providing the basis for the score. The diagnostic performance of the clinical score was assessed using the c statistic for discrimination (area under the receiver operating curve) and the Hosmer–Lemeshow goodness of fit for calibration. We then identified score thresholds at 98% sensitivity and 98% specificity for midwall myocardial fibrosis, accepting a combined false-positive and -negative rate of <5%. These values would define the risk categories of patients in the outcome cohorts.

Validation of clinical score and cardiovascular outcomes
Using our clinical score, the predicted probability (P) for midwall myocardial fibrosis was calculated for each patient in the internal and external outcome cohorts, according to the equation: 

\[ P = \exp(y)/[1 + \exp(y)] \]

where \( y = \beta_0 + \sum \beta_i X_i \) where \( \beta_0 \) is the constant of the logistic equation, \( \beta_i \) is the regression coefficient of each variable, and \( X_i \) is the clinical model. In practice, the clinical score and the corresponding risk category for each patient were obtained easily using our online calculator (see Aortic Stenosis Risk Calculator, Supplementary material online) or a nomogram (Figure 1). The clinical score is also available in the mobile app Calculate by QxMD on iOS, Android and Windows (http://qxmd/calculate) and on the web at qxmd.com/as-risk-score.

Patients with scores less than the threshold at 98% sensitivity for midwall myocardial fibrosis were classified as low risk. Conversely, patients with scores greater than the threshold at 98% specificity for midwall myocardial fibrosis were classified as high risk. All others were at intermediate risk. Time-to-first event survival curves associated with the different risk categories were estimated using the Kaplan–Meier method and compared with the log-rank test.

Results
Cardiovascular magnetic resonance derivation cohort
One hundred and sixty-six patients with AS were recruited in the CMR derivation cohort. We excluded 15 patients with myocardial infarction and 5 patients without blood samples (1 patient with myocardial infarction did not have blood samples). Compared with patients without midwall fibrosis (n = 103), those with midwall fibrosis (n = 44) had more severe AS and elevated markers of LV decompensation (P < 0.001 for all; Table 1). Thirty-seven patients in the CMR derivation cohort had symptoms consistent with severe AS.

The final clinical score of age, sex, high-sensitivity cTnI concentrations (log_{10} transformed), \( V_{\text{max}} \) (log, transformed), and ECG strain demonstrated excellent discrimination (c statistics = 0.85; 95% confidence interval 0.78–0.91; P < 0.001) and calibration (Hosmer–Lemeshow \( \chi^2 = 7.33; P = 0.50; \) Table 2), and it outperformed other determinants of midwall myocardial fibrosis (Table 3). The risk probabilities that corresponded to 98% sensitivity and 98% specificity for midwall fibrosis were 7.0 and 57.0%, respectively. On this basis, 14% of patients (n = 21) in the CMR derivation cohort were at low risk of midwall myocardial fibrosis (risk score < 7.0%) and 19% (n = 28) at high risk (risk score > 57.0%). Among those at intermediate risk (n = 98), 18% had midwall myocardial fibrosis on CMR. Of note, the clinical score correlated well with diastolic function (r = 0.31; P < 0.001), CMR longitudinal function (r = −0.42; P < 0.001), and fibrosis volume assessed using myocardial T1 mapping (r = 0.66; see Supplementary material online).

Association between clinical score and adverse events
Internal outcome cohort
In this cohort, 127 asymptomatic patients were analysed (69 [62,75] years, 70% males, \( V_{\text{max}} 3.4 [2.9,4.0] \) m/s after excluding patients without blood samples (n = 24). Using the two risk thresholds established from the CMR derivation cohort, 13% of the patients (n = 17) in the internal outcome cohort were classified as low risk and 15% (n = 19) as high risk. While no low-risk patients had \( V_{\text{max}} \geq 4.0 \) m/s, 42% of high-risk patients had \( V_{\text{max}} \) between 3.0 and 3.9 m/s (Table 4).

There were 62 AS-related events (cardiovascular mortality, n = 26; congestive heart failure and new symptoms, n = 36) over 10.3 [5.7,11.2] years of follow-up (704.6 patient-years; 8.8 events/100 patient-years). In low-risk patients, only three AS-related events were observed. Conversely, high-risk patients had over a 10-fold increase in the AS-related event rate (23.9 vs. 2.1 events/100 patient-years in low-risk patients; log rank P < 0.001; Figure 2; Table 4), which all occurred early and within the first 5 years.

Similar findings were observed with mortality rates. Forty-six patients died (26 from cardiovascular causes) during follow-up. In the low-risk group, there were no cardiovascular deaths during the entire period of follow-up. Three patients died from non-cardiac causes with no deaths within the first 5 years. By comparison, mortality rates were ~7-fold higher in high-risk patients (13.0 vs. 2.1 all-cause deaths/100 patient-years in low-risk patients; log rank P < 0.001; Figure 3), and cardiovascular causes accounted for more than two-thirds of the deaths.

External outcome cohort
A total of 289 patients were analysed (74 [67,80] years, 72% males, \( V_{\text{max}} 3.0 [2.5,3.6] \) m/s), after excluding patients without blood samples (n = 18) or interpretable ECGs (n = 25; Table 5). In this cohort, 16% (n = 45) and 8.0% (n = 23) of the patients were classified as low and high risk, respectively. Two low-risk patients
had $V_{\text{max}} = 4.0 \text{ m/s}$ while 30% of high-risk patients had $V_{\text{max}}$ between 3.0 and 3.9 (Table 4). Over 2.6 [1.6,4.5] years of follow-up (854.9 patient-years), there were 76 AS-related events (cardiovascular deaths, $n = 9$; congestive heart failure and new symptoms, $n = 67$) and an event rate similar to the internal outcome cohort (8.9 AS-related events/100 patient-years). The prognosis of low-risk patients was very favourable: only 7 events throughout the follow-up with no events in the first 2 years. Conversely, high-risk patients had substantially worse outcomes (31.6 vs. 4.6 AS-related events/100 patient-years in low-risk patients; log-rank test $P < 0.001$; Figure 2), and these events occurred very early (median time to event of 1.5 years). Compared with the internal outcome cohort, the external outcome cohort had a much shorter duration of follow-up and not unexpectedly, a considerably lower mortality rate that precluded further detailed analysis.

**Incremental prognostic value of clinical score**

We examined in greater detail the prognostic value of the clinical score. Addition of high-sensitivity cTnl and ECG strain in the score provided incremental prognostic value, over and above $V_{\text{max}}$. 

---

**Figure 1** Nomogram for aortic stenosis clinical score. The risk probability can be also calculated using a nomogram. For example, a 50-year-old female patient with peak aortic jet velocity of 4.0 m/s, high-sensitivity cardiac troponin concentration of 30 ng/L and electrocardiogram strain pattern would have a risk probability of 78% (high risk).
Table 1  Baseline characteristics of patients in the cardiovascular magnetic resonance cohort

| Clinical characteristics             | All patients (N = 147) | No midwall myocardial fibrosis (N = 103) | Midwall myocardial fibrosis (N = 44) | P  |
|--------------------------------------|------------------------|------------------------------------------|--------------------------------------|----|
| Age (years)                          | 70 [63.76]             | 70 [63.76]                               | 71 [65.78]                           | 0.42|
| Male, n (%)                          | 99 (68)                | 66 (67)                                  | 33 (70)                              | 0.20|
| Diabetes mellitus, n (%)             | 21 (14)                | 15 (15)                                  | 6 (13)                               | 0.64|
| CAD, n (%)                           | 47 (32)                | 29 (29)                                  | 18 (38)                              | 0.34|
| SBP (mmHg)                           | 151 ± 21               | 151 ± 22                                 | 153 ± 19                             | 0.41|
| hsTnI concentration (ng/L)           | 6.0 [3.6,11.6]         | 4.6 [3.2,8.0]                            | 10.8 [6.6,26.5]                      | <0.001|
| BNP concentration (pg/mL)            | 24.7 [10.4,53.1]       | 21.8 [7.3,43.4]                          | 34.4 [12.4,87.5]                     | 0.01|
| ECG strain, n (%)                    | 22 (15)                | 0                                        | 22 (46)                              | <0.001|
| Echocardiography                     |                        |                                          |                                      |    |
| Vmax (m/s)                           | 3.9 [3.2,4.4]          | 3.7 [2.9,4.2]                            | 4.1 [3.8,4.6]                        | <0.001|
| MPG (mmHg)                           | 33 [22.43]             | 29 [17.40]                               | 37 [29.50]                           | <0.001|
| AVA (cm²)                            | 0.88 [0.73,1.11]       | 0.96 [0.74,1.20]                         | 0.81 [0.73,0.91]                     | 0.008|
| LVM, (g/m²)                          | 122 ± 32               | 116 ± 29                                 | 137 ± 34                             | <0.001|
| Diastolic function (E/e′)            | 12.6 [10.1,16.7]       | 11.7 [8.9,15.2]                          | 14.5 [12.3,19.9]                     | <0.001|
| CMR                                  |                        |                                          |                                      |    |
| EDVi (mL/m²)                          | 69 [61.78]             | 68 [60.76]                               | 72 [65.88]                           | 0.03|
| ESVi (mL/m²)                         | 23 [18.27]             | 22 [18.26]                               | 24 [20.30]                           | 0.08|
| SVi (mL/m²)                          | 47 [41.54]             | 46 [40.53]                               | 49 [43.58]                           | 0.05|
| LVEF (%)                             | 67 [63.71]             | 68 [64.71]                               | 67 [63.71]                           | 0.55|
| Longitudinal function (mm)           | 12.3 ± 2.9             | 13.0 ± 2.6                               | 10.9 ± 3.1                           | <0.001|
| LVMi (g/m²)                          | 87 [73.99]             | 80 [67.91]                               | 101 [93.118]                         | <0.001|
| LVMi/EDVi (g/mL)                     | 1.26 ± 0.27            | 1.18 ± 0.24                              | 1.42 ± 0.27                          | <0.001|

CAD, coronary artery disease; SBP, systolic blood pressure; hsTnI, high-sensitivity cardiac troponin I; BNP, brain natriuretic peptide; NT-proBNP, N-terminal proBNP; ECG strain, electrocardiographic left ventricular hypertrophy with strain; Vmax, peak aortic jet velocity; MPG, mean pressure gradient; AVA, aortic valve area; LVM, indexed left ventricular mass; EDVi, indexed end-diastolic volume; ESVi, indexed end-systolic volume; SVi, indexed stroke volume; LVEF, left ventricular ejection fraction.

Table 2  Clinical determinants of midwall myocardial fibrosis

| Variable                                | Univariate Regression coefficient (standard error) | P     | Clinical model Regression coefficient (standard error) | P     |
|-----------------------------------------|---------------------------------------------------|-------|-------------------------------------------------------|-------|
| Age (years)                             | 0.021 (0.016)                                      | 0.19  | 0.047 (0.027)                                         | 0.08  |
| Male                                    | 0.692 (0.400)                                      | 0.08  | 1.356 (0.651)                                         | 0.04  |
| Presence of CAD                         | 0.007 (0.008)                                      | 0.64  | –                                                     | –     |
| Vmax (m/s)b                             | 3.514 (0.922)                                      | <0.001| 2.319 (1.282)                                         | 0.07  |
| hsTnI concentration (ng/L)c            | 2.133 (0.486)                                      | <0.001| 0.935 (0.604)                                         | 0.12  |
| BNP concentration (pg/mL)b             | 1.056 (0.424)                                      | 0.01  | –                                                     | –     |
| ECG strain                              | 4.364 (1.046)                                      | <0.001| 3.616 (1.145)                                         | 0.002 |
| Constant                                | –                                                 | –     | –                                                     | –     |

For abbreviations, see Table 1.

bBrain natriuretic peptide was selected in the initial multivariate model but it was not retained in the final clinical score using backward elimination.

cValues were loge transformed.

cValues were log10 transformed.
Table 3  Performance of determinants associated with midwall myocardial fibrosis

| Discrimination | Calibration |
|----------------|-------------|
|                | c statistics (95% CI) | P | x² | P |
| V\(_{\text{max}}\) | 0.70 (0.62–0.79) | <0.001 | 6.5 | 0.58 |
| BNP concentration | 0.63 (0.52–0.74) | 0.016 | 13.5 | 0.06 |
| hsTnI concentration | 0.76 (0.68–0.85) | <0.001 | 15.0 | 0.06 |
| ECG strain | 0.71 (0.62–0.81) | <0.001 | NA | NA |
| Clinical score\(^a\) | 0.85 (0.78–0.91) | <0.001\(^a\) | 7.3 | 0.50 |

For abbreviations, see Table 1.

\(^a\)The clinical score consisted of age, sex, V\(_{\text{max}}\), hsTnI concentrations, and ECG strain.

\(^a\)P < 0.05 when compared with V\(_{\text{max}}\), BNP concentration and ECG strain; P = 0.07 when compared with hsTnI concentration.

Table 4  Relevant characteristics of patients in the cardiovascular magnetic resonance and outcome cohorts risk stratified by probabilities of midwall myocardial fibrosis

| Low risk (probability <7%) | CMR cohort (N = 21) | Internal outcome cohort (N = 17) | External outcome cohort (N = 45) |
|---------------------------|---------------------|-------------------------------|-------------------------------|
| Age (years) | 63 [48.69] | 57 [49.66] | 70 [61.74] |
| Males, n (%) | 3 (14) | 3 (18) | 4 (9) |
| V\(_{\text{max}}\) (m/s) | 2.8 [2.5,3.2] | 3.0 [2.7,3.4] | 2.6 [2.4,2.9] |
| ECG strain, n (%) | 0 | 0 | 0 |
| hsTnI concentration (ng/L) | 2.1 [1.5,4.0] | 5.4 [4.0,6.6] | 4.1 [3.0,6.4] |
| Patients with V\(_{\text{max}}\) 3.0–3.9 m/s, n (%) | 5 (24) | 10 (59) | 6 (13) |
| Patients with V\(_{\text{max}}\) ≥ 4.0 m/s, n (%) | 1 (5) | 0 | 2 (4) |
| AS-related events, n (%) | NA | 3 (18) | 7 (16) |

| Intermediate risk (probability 7–57%) | CMR cohort (N = 98) | Internal outcome cohort (N = 91) | External outcome cohort (N = 221) |
|--------------------------------------|---------------------|-------------------------------|-------------------------------|
| Age (years) | 71 [66.77] | 69 [63.75] | 75 [67.80] |
| Males, n (%) | 74 (76) | 71 (78) | 186 (84) |
| V\(_{\text{max}}\) (m/s) | 3.8 [3.3,4.2] | 3.3 [2.8,4.0] | 3.1 [2.6,3.5] |
| ECG strain, n (%) | 0 | 0 | 0 |
| hsTnI concentration (ng/L) | 5.3 [3.8,9.5] | 7.6 [5.8,12.2] | 7.0 [5.0,11.0] |
| Patients with V\(_{\text{max}}\) 3.0–3.9 m/s, n (%) | 47 (48) | 40 (44) | 96 (43) |
| Patients with V\(_{\text{max}}\) ≥ 4.0 m/s, n (%) | 37 (38) | 24 (26) | 27 (12) |
| AS-related events, n (%) | NA | 47 (52) | 56 (25) |

| High risk (probability >57%) | CMR cohort (N = 28) | Internal outcome cohort (N = 19) | External outcome cohort (N = 23) |
|-----------------------------|---------------------|-------------------------------|-------------------------------|
| Age (years) | 71 [62.78] | 75 [66.77] | 79 [72.84] |
| Males, n (%) | 22 (79) | 15 (79) | 19 (83) |
| V\(_{\text{max}}\) (m/s) | 4.6 [4.1,5.1] | 4.1 [3.5,4.4] | 3.9 [3.1,4.4] |
| ECG strain, n (%) | 22 (92) | 19 (100) | 17 (74) |
| hsTnI concentration (ng/L) | 25.2 [10.1,46.7] | 17.3 [10.5,29.6] | 14.0 [9.0,21.0] |
| Patients with V\(_{\text{max}}\) 3.0–3.9 m/s, n (%) | 4 (14) | 8 (42) | 7 (30) |
| Patients with V\(_{\text{max}}\) ≥ 4.0 m/s, n (%) | 24 (86) | 10 (53) | 11 (48) |
| AS-related events, n (%) | NA | 12 (63) | 13 (57) |

For abbreviations, see Table 1.
age and sex (global $\chi^2$ increased from 117 to 133; $P = 0.03$; Figure 3). In particular, across the two outcome cohorts, similar improvement in risk stratification was observed in patients stratified by either median age or sex (log-rank test $P < 0.001$ for all analyses; Figure 4).

Among patients with at least moderate AS (either $V_{\text{max}} \geq 3.0$ m/s or aortic valve area $\leq 1.5$ cm$^2$), the clinical score further improved risk-stratification and identified patients with very low- and high-event rates (log rank $P < 0.001$ for both; Figure 5). Of note, the remaining patients at intermediate risk had an event rate almost identical to the natural history of the patients with moderate and severe AS (green dotted line; Figure 5).

**Figure 2** Aortic stenosis-related events stratified according to the risk of midwall myocardial fibrosis in the internal outcome cohort (A) and external outcome cohort (B).

**Figure 3** Cardiovascular (A) and all-cause mortality (B) in the internal outcome cohort.

**Discussion**

In a large CMR cohort of patients with AS, we have proposed the first clinical score consisting of variables associated with midwall myocardial fibrosis, an early and important marker of LV decompensation. This simple clinical score demonstrated excellent diagnostic performance for midwall myocardial fibrosis on CMR. Using the novel thresholds and across $>400$ asymptomatic patients (1560 patient-years), those at high risk (11% of patients in both outcome cohorts) had extremely poor outcomes while low-risk patients (16%) had very favourable prognosis. The clinical score has demonstrated important prognostic information in identifying patients who...
either may benefit from early AVR or can continue conservative surveillance.

Current guidelines recommend AVR in patients with severe AS and the evidence of LV decompensation based on either symptoms or a systolic ejection fraction <50%.19,20 However, symptoms are often difficult to elucidate in the elderly in whom adequate exercise stress testing may also be challenging. Furthermore, a low ejection fraction is a late manifestation and frequently irreversible. There is therefore considerable interest in examining novel and objective markers of LV decompensation to identify patients who may benefit from early AVR.1,2 The transition from hypertrophy to heart failure in AS is driven by progressive myocyte cell death and myocardial fibrosis. Cardiovascular magnetic resonance is able to visualize the latter directly, making it an attractive imaging modality to detect early decompensation. Indeed, we and others have reported that midwall fibrosis on CMR is not only associated with multiple features of LV decompensation but also an adverse prognosis in patients with AS.5–9

Unfortunately, the limited availability and relatively high costs of CMR may make routine surveillance impractical for all patients with AS. Consequently, a clinical score that is associated with midwall fibrosis is potentially attractive, particularly one that can also demonstrate prognostic value. In this study, we have developed such a score consisting of variables that can easily be obtained in routine clinical care. In addition to age, sex, and AS severity, both high-sensitivity cTnI and ECG strain pattern were retained in the final model as independent predictors of midwall fibrosis, consistent with recent literature.10,11 Rather than individual determinants, an integrated approach of using the clinical score performed best at identifying midwall myocardial fibrosis. In particular, one cannot simply rely on the traditional markers of AS severity (such as Vmax) as the magnitude of the hypertrophic response and the rate of LV decompensation are highly variable between patients.1,21–23 Although plasma BNP concentrations were associated with midwall myocardial fibrosis, the association was absent when other variables were considered. It is likely that BNP and NT-proBNP are released in the later stages of LV decompensation when symptoms develop and are therefore, not sensitive markers of midwall myocardial fibrosis or LV decompensation at an earlier state of the disease.

After the score was derived, we further established novel thresholds that might risk-stratify patients according to the probability of myocardial fibrosis. We have decided a priori to use stringent thresholds to define the high- and low-risk categories in order to minimize the false-positive and -negative rates of midwall fibrosis (<5%) and to maximize the score’s ability to confidently identify low- and high-risk patients.

The prognostic ability of the clinical score and associated thresholds was then validated across two independent cohorts of >400 patients. To our knowledge, this is the largest validation cohort used to test a clinical score in AS. Low-risk patients identified by the score had a favourable prognosis: 16% of them had an AS-related event and only one cardiovascular death over a median time of 4.3 years. Conversely, high-risk patients had very poor outcomes: 67% of them had either an AS-related event or died over a median of 1.9 years, and these events occurred early. The clinical score demonstrated similar findings regardless of age and sex, and provided incremental prognostic information over conventional echocardiographic assessment of AS severity. Importantly, these

| Table 5 | Baseline characteristics of patients in the internal and external outcome cohorts |
|---------|---------------------------------------------------------------------------------|
|         | Internal outcome cohort (N = 127)                                               | External outcome cohort (N = 289) | P       |
|         |                                                                                   |                                  |         |
| Clinical characteristics |                                                                                   |                                  |         |
| Age (years)  | 69 [62,75]                                                                           | 74 [67,80]                       | <0.001  |
| Male, n (%)     | 89 (70)                                                                             | 209 (72)                        | 0.88    |
| Diabetes mellitus, n (%) | 4 (3)                                                                            | 73 (25)                        | <0.001  |
| CAD, n (%)       | 22 (17)                                                                            | 88 (30)                         | 0.04    |
| SBP (mmHg)       | 145 ± 19                                                                           | 126 ± 18                        | <0.001  |
| hsTnI concentration (ng/L) | 7.6 [5.7,13.4]                                      | 7.0 [4.8,11.0]                   | 0.03    |
| NT-proBNP concentration (pg/mL) | 198 [121,531]                              | 169 [73,419]                     | 0.07    |
| ECG strain, n (%) | 19 (15)                                                                            | 18 (6)                          | 0.06    |
| Echocardiography |                                                                                   |                                  |         |
| Vmax (m/s)       | 3.4 [2.9,4.0]                                                                       | 3.0 [2.6,3.6]                    | <0.001  |
| Number of patients, n (%) |                                                                |                                  |         |
| <3.0 m/s         | 35 (27)                                                                            | 140 (48)                        | <0.001  |
| 3.0–3.9 m/s      | 58 (46)                                                                            | 109 (38)                        |         |
| ≥4 m/s           | 34 (27)                                                                            | 40 (14)                         |         |
| MPG (mmHg)       | 24 [17,35]                                                                          | 21 [15,31]                      | 0.01    |
| AVA (cm²)        | 1.01 [0.72,1.28]                                                                    | 1.35 [1.10,1.60]                 | <0.001  |
| LVMi (g/m²)      | 142 [121,167]                                                                       | 116 [94,138]                     | <0.001  |
| LVEF (%)         | 70 [64,78]                                                                          | 63 [63,68]                      | <0.01    |

For abbreviations, see Table 1.
improvements in risk stratification were observed in patients with moderate and severe disease.

**Clinical implications**

Our observations have indirectly strengthened the prognostic association between CMR midwall fibrosis and cardiovascular outcomes. Potentially, asymptomatic patients with advanced AS can initially be risk stratified using this clinical score. Patients at low risk can be managed conservatively with regular reassessment of risk, while those at high risk (particularly those with severe AS) can be considered for early AVR. Finally, patients with intermediate-risk scores can undergo further risk stratification (such as CMR to definitively assess the presence of midwall myocardial fibrosis, computed tomography aortic valve calcium scores, or exercise
stress testing). Our risk score will therefore guide clinical management in 25–30% of patients with AS, without the need for further investigations. This is a cost-effective strategy to guide the timing of AVR using more objective markers of LV decompensation. Ultimately, such an approach will need to be tested in a randomized controlled trial.

**Study limitations**

This study is limited by a relatively short duration of follow-up in the external outcome cohort. Therefore, the lower mortality rates in the external outcome cohort precluded further detailed analysis. We had excluded patients with prior myocardial infarction from the CMR derivation cohort so as to derive an accurate clinical score of midwall myocardial fibrosis due to AS. Nevertheless, the findings remained unchanged when patients with prior myocardial infarction were included in the derivation of the score (see Supplementary material online). Finally, CMR was not performed in the two outcome cohorts and we were unable to reconfirm the presence of midwall fibrosis in these patients.

**Conclusions**

We have developed a clinical risk score consisting of variables associated with midwall myocardial fibrosis. This score demonstrates strong prognostic information in asymptomatic patients with AS and holds major potential in identifying those who may benefit from early AVR.

**Supplementary material**

Supplementary material is available at *European Heart Journal* online.
Authors’ contribution

C.C., D.M.-Z., A.S., T.M.: performed statistical analysis. D.E.N., M.R.D.: handled funding and supervision. D.M.-Z., T.M., E.N.W.Y., M.K., G.L., S.B.: acquired the data. C.C., D.M.-Z.: conceived and designed the research. C.C., D.M.-Z., D.N., M.D.: drafted the manuscript. C.C., D.M.-Z., A.S., G.L., S.B., M.M., S.S., N.M., A.V., D.N., M.D.: made critical revision of the manuscript for key intellectual content. S.S.: optimize MRI sequences crucial for the study. S.M.: read the MRI images alongside Calvin Chin and Marc Dweck—the names of the authors who did anything else on the manuscript other than what we have listed.

Acknowledgements

The Wellcome Trust Clinical Research Facility and the Clinical Research Imaging Centre, Edinburgh assisted in the conduct of the study. Mary Stoddard and Edwin Carter assisted with the analysis of high-sensitivity plasma cardiac troponin I concentrations and Abbott Laboratories for providing the assay reagents. Le Thu Thao wrote the program for the online clinical calculator and Leif Roschier designed the nomogram using PyNomo. We thank the Department of Biochemistry of Bichat Hospital, Paris (Dr Monique Dehoux) and the technician of the Department of Biochemistry of Tenon Hospital, Paris (Marie Christine Ricon et Alicia Poniard).

Funding

A.S.V.S., N.L.M., D.E.N., and M.R.D. are supported by the British Heart Foundation (CH/09/002, FS/10/024, FS/10/26, and FS/14/78/31020). D.E.N. holds a Wellcome Trust Senior Investigator Award (WT103782AIA). C.W.L.C. is supported by the National Research Foundation-Ministry of Health, Singapore. The Wellcome Trust Clinical Research Facility and the Clinical Research Imaging Centre are supported by the NHS Research Scotland through NHS Lothian. The COFRASA (clinicalTrials.gov number NCT00338676) and GENERAC (clinicalTrials.gov number NCT00647088) studies are supported by grants from the Assistance Publique–Hôpitaux de Paris (PHRC National 2005 and 2010 and PHRC regional 2007). Funding to pay the Open Access publication charges for this article was provided by the British Heart Foundation.

Conflict of interest

A.S.V.S., G.L., and N.L.M. received speaker fees from Abbott Laboratories, and N.L.M. has acted as a consultant for Beckman-Coulter.

References

1. Chin CW, Vassiliou V, Jenkins WS, Prasad SK, Newby DE, Dweck MR. Markers of left ventricular decompensation in aortic stenosis. Expert Rev Cardiovasc Ther 2014; 12:901–912.
2. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 2012;60:1854–1863.
3. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, Bauer EP, A.S.V.S., G.L., and N.L.M. received speaker fees from Abbott Laboratories, and N.L.M. has acted as a consultant for Beckman-Coulter.
4. Weidemann F, Herrmann S, Storck S, Niemann M, Fratz S, Lange V, Beer M,Gattelöhner S, Voelker W, Erti G, Strotmann JM. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120:577–584.
5. Quarto C, Dweck MR, Murigiu T, Joshi S, Melina G, Angeloni E, Prasad SK, Pepper JR. Late gadolinium enhancement as a potential marker of increased perioperative risk in aortic valve replacement. Interact Cardiovasc Thorac Surg 2012;15:45–50.
6. Azvedo CF, Nigr M, Higuchi ML, Pomerantz MM, Spina GS, Sampayo RO, Tarasoutchi F, Grinberg M, Rochitte CE. Prognostic significance of myocardial fibrosis quantification by magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol 2010;56:278–287.
7. Milano AD, Faggian G, Dodonov M, Golia G, Tommaso A, Bortolotti U, Mazzucco A. Prognostic value of myocardial fibrosis in patients with aortic stenosis. J Thorac Cardiovasc Surg 2010;144:830–837.
8. Barone-Rochette G, Pérard S, De Meester de Ravenstein C, Seldrum S, Melchor J, Mazzucco A. Prognostic value of myocardial fibrosis in patients with aortic stenosis. Eur Heart J 2014;35:3132–3133.
9. Shah AS, Chin CW, Vassiliou V, Cowell SJ, Doris M, Kwok TC, Semple S, Zamvar V, White AC, McKillop G, Boon NA, Prasad SK, Mills NL, Dweck MR. Left ventricular hypertrophy with strain and aortic stenosis. Circulation 2014;130:1607–1616.
10. Chin CW, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389–2397.
11. Romhilt DW, Estes EH. A point-score system for the ECG diagnosis of left ventricular hypertrophy. Am Heart J 1968;75:752–758.
12. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS, Bailey J, Childers R, Gorgels A, Josephson M, Kors JA, Macfarlane P, Mason JW, Pahlom O, Rautaharju PM, Surawicz B, van Herpen G, Wagner GS, Wellsens H. AHA/ACC/FHS recommendations for the standardization and interpretation of the electrocardiogram. J Am Coll Cardiol 2009;53:992–1002.
13. Baumgartner H, Hung J, Blumen C, Chambers JB, Evangelista A, Griffin BP, Jung B, Otto CM, Pelikka PA, Quinones M. Echocardiographic assessment of valve stenosis: EAE/AESE recommendations for clinical practice. J Am Soc Echocardiogr 2009;22:1–23.
14. Krintus M, Kozinski M, Boudry P, Capell NE, Köller U, Lackner K, Lefèvre G, Schaffers HJ, Evangelista A, Vaxillaire M, Prasad NA, Wage R, Quarto C, Angeloni E, Refice S, Gattenlohner S, Voelker W, Erti G, Strotmann JM. Impact of myocardial fibrosis in patients with aortic stenosis. J Cardiovasc Magn Reson 2012;14;e185.
15. Roche NT-pro BNP assay [Package Insert]. 2006. http://www.rochecanada.com/content/dam/internet/corporate/rochecanada/en_CA/documents/package_inserts/ProBNPII-04842464190-EN-V9-CAN.pdf (1 February 2015)
16. Roche NT-pro BNP assay [Package Insert]. 2006. http://www.rochecanada.com/content/dam/internet/corporate/rochecanada/en_CA/documents/package_inserts/ProBNPII-04842464190-EN-V9-CAN.pdf (1 February 2015).